Wafik S. El-Deiry, Director of Legorreta Cancer Center at Brown University and Chair of the WIN Consortium in Cancer Personalized Medicine, shared a post on LinkedIn:
“Glad to see the eldeirylab’s citations at sustained levels as I complete 7 years at Brown University.
I am proud of the lab members and colleagues who have contributed to this success especially at difficult times in academic medicine. The impact has been felt in Rhode Island and in the cancer research/Oncology community.
This year it was exciting to see that a drug discovered in the eldeirylab in 2007 (building on the prior 12 years of progress after discovery of TRAIL receptor DR5 in the lab) as a TRAIL-Inducing Compound (TIC10), licensed to Oncoceutics and developed as ONC201 and acquired by Chimerix was the first approval by the US FDA as Dordaviprone/Modeyso through Jazz Pharmaceuticals for aggressive H3K27M-mutated brain tumors.
I have said previously that US support of biomedical research is badly broken and this has gotten worse in the most recent years. Labs such as this one are worth preserving in order to continue to find cures for cancer. Conducting impactful scientific research in the US should not be a daily struggle for survival. It is shameful.”
